One revolutionary drug class used in the treatment of IBD is monoclonal antibodies such as Infliximab which, through targeted sequestration of the pro-inflammatory cytokine TNFα, has effectively reduced disease burden in numerous patients. This evidence concerns the gene TNF and inflammatory bowel disease.